Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$772M |
| 2 |
Eli Lilly
LLY
|
+$337M |
| 3 |
lululemon athletica
LULU
|
+$301M |
| 4 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$297M |
| 5 |
ResMed
RMD
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$576M |
| 2 |
AT&T
T
|
+$476M |
| 3 |
PNC Financial Services
PNC
|
+$393M |
| 4 |
Fortive
FTV
|
+$389M |
| 5 |
Accenture
ACN
|
+$374M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 2.83% |
| 2 | Technology | 2.79% |
| 3 | Financials | 2.29% |
| 4 | Consumer Discretionary | 1.93% |
| 5 | Industrials | 1.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
8926
Nerdy
NRDY
$86.8M
| $424K | ﹤0.01% |
198,956
+70,902
| +55% | +$231K |
|
8927
Hartford Multifactor Emerging Markets ETF
ROAM
$112M
| $424K | ﹤0.01% |
+21,154
| New | +$460K |
|
|
SGMO
8928
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $424K | ﹤0.01% |
102,500
+11,000
| +12% | +$47.6K |
|
8929
WBI BullBear Value 3000 ETF
WBIF
$23.5M
| $424K | ﹤0.01% |
14,382
-31,195
| -68% | -$958K |
|
|
HCIC
8930
PUT
DELISTED
Hennessy Capital Investment Corp. V Class A Common Stock
HCIC
| $424K | ﹤0.01% |
43,200
-35,500
| -45% | -$348K |
|
8931
CALL
Conduent
CNDT
$229M
| $423K | ﹤0.01% |
97,900
-47,600
| -33% | -$239K |
|
8932
PUT
FS KKR Capital
FSK
$3.31B
| $423K | ﹤0.01% |
21,800
-12,700
| -37% | -$269K |
|
|
LADR
8933
PUT
Ladder Capital
LADR
$1.25B
| $423K | ﹤0.01% |
40,100
-6,200
| -13% | -$70.3K |
|
8934
PUT
Myriad Genetics
MYGN
$291M
| $423K | ﹤0.01% |
23,300
-7,900
| -25% | -$164K |
|
8935
CALL
Ingevity
NGVT
$2.61B
| $423K | ﹤0.01% |
6,700
-15,700
| -70% | -$1.02M |
|
8936
PUT
Xenon Pharmaceuticals
XENE
$6.03B
| $423K | ﹤0.01% |
13,900
-4,200
| -23% | -$127K |
|
|
DMTK
8937
CALL
DELISTED
DermTech, Inc. Common Stock
DMTK
| $423K | ﹤0.01% |
76,400
+4,300
| +6% | +$35.2K |
|
|
RADA
8938
DELISTED
Rada Electronic Industries Ltd
RADA
| $423K | ﹤0.01% |
45,744
+10,385
| +29% | +$134K |
|
8939
iShares MSCI Austria ETF
EWO
$209M
| $422K | ﹤0.01% |
23,363
+5,679
| +32% | +$115K |
|
8940
CALL
TechnipFMC
FTI
$31.3B
| $422K | ﹤0.01% |
62,700
-50,000
| -44% | -$381K |
|
8941
CALL
Global Net Lease
GNL
$2.04B
| $422K | ﹤0.01% |
29,800
-4,700
| -14% | -$67.2K |
|
8942
Invesco S&P 500 Equal Weight Energy ETF
RSPG
$613M
| $422K | ﹤0.01% |
6,865
-12,011
| -64% | -$841K |
|
8943
RxSight
RXST
$270M
| $422K | ﹤0.01% |
+29,988
| New | +$396K |
|
|
SVFAU
8944
DELISTED
SVF Investment Corp. Unit
SVFAU
| $422K | ﹤0.01% |
42,799
+22,682
| +113% | +$224K |
|
8945
CALL
America Movil
AMX
$71B
| $421K | ﹤0.01% |
20,600
+5,300
| +35% | +$109K |
|
8946
Business First Bancshares
BFST
$1.05B
| $421K | ﹤0.01% |
19,742
-15,444
| -44% | -$342K |
|
8947
Standard BioTools
LAB
$269M
| $421K | ﹤0.01% |
263,281
+208,289
| +379% | +$515K |
|
|
NVRO
8948
PUT
DELISTED
NEVRO CORP.
NVRO
| $421K | ﹤0.01% |
9,600
-11,200
| -54% | -$616K |
|
8949
Avantis International Large Cap Value ETF
AVIV
$2.07B
| $420K | ﹤0.01% |
+9,872
| New | +$465K |
|
8950
Pathward Financial
CASH
$1.77B
| $420K | ﹤0.01% |
+10,853
| New | +$463K |
|
Similar funds
Ken Griffin's Q2 2022 Portfolio in Review
As of Q2 2022, Ken Griffin held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Ken Griffin's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.
By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.
- Ken Griffin's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
- Ken Griffin added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
- Ken Griffin's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
- Ken Griffin fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
- Ken Griffin's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
- Ken Griffin opened 1,520 new positions and closed 2,191 in Q2 2022.
- Ken Griffin's portfolio value fell 20% quarter-over-quarter to $390B.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.